Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network
(چکیده مقاله) :
Abstract :
In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of
emergency measures and a degradation in the organization of neuromuscular reference centers.
In this special context, the French Rare Health Care for Neuromuscular Diseases Network
(FILNEMUS) has established guidance in an attempt to homogenize the management of
neuromuscular (NM) patients within the French territory. Hospitalization should be reserved
for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the
diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for
which the delay could be detrimental to the patient. A national strategy was adopted during a
period of 1 to 2 months concerning treatments usually administered in hospitalization. NM
patients treated with steroid/ immunosuppressants for a dysimmune pathology should continue
all of their treatments in the absence of any manifestations suggestive of COVID-19. A
frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS
website. Various support systems for self-rehabilitation and guided exercises have been also
provided on the website. In the context of NM diseases, particular attention must be paid to
two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of
exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac
involvement. The unfavorable emergency context related to COVID-19 may s
coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of
emergency measures and a degradation in the organization of neuromuscular reference centers.
In this special context, the French Rare Health Care for Neuromuscular Diseases Network
(FILNEMUS) has established guidance in an attempt to homogenize the management of
neuromuscular (NM) patients within the French territory. Hospitalization should be reserved
for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the
diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for
which the delay could be detrimental to the patient. A national strategy was adopted during a
period of 1 to 2 months concerning treatments usually administered in hospitalization. NM
patients treated with steroid/ immunosuppressants for a dysimmune pathology should continue
all of their treatments in the absence of any manifestations suggestive of COVID-19. A
frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS
website. Various support systems for self-rehabilitation and guided exercises have been also
provided on the website. In the context of NM diseases, particular attention must be paid to
two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of
exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac
involvement. The unfavorable emergency context related to COVID-19 may s
(توضیحات تکمیلی) :
(توضیحات تکمیلی) :
Description :
مقاله ISI انگلیسی اصلی
سال انتشار: 2020
فایل ISI انگلیسی اصلی ، با فرمت Pdf
تعداد صفحات فایل ISI انگلیسی اصلی: 22 صفحه
سال انتشار: 2020
فایل ISI انگلیسی اصلی ، با فرمت Pdf
تعداد صفحات فایل ISI انگلیسی اصلی: 22 صفحه
Authors / Descriptions(نویسندگان/توضیحات): سال انتشار 2020 \ مقاله ISI انگلیسی اصلی
Sent date(تاریخ ارسال) :
1399/02/04 | 4/23/2020
Number of visits(تعداد بازدید):
874
Key words (کلمات کلیدی):
COVID-19; neuromuscular; treatment; management; guidelines
Number of pages(تعداد صفحات) :
22
| نظرات کاربران در مورد این آگهی | |
|
در حال حاضر هیچ نظری ثبت نگردیده است .
|
|